Publication: Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.
| dc.contributor.author | Nicoletti, Paola | |
| dc.contributor.author | Barrett, Sarah | |
| dc.contributor.author | McEvoy, Laurence | |
| dc.contributor.author | Daly, Ann K | |
| dc.contributor.author | Aithal, Guruprasad | |
| dc.contributor.author | Lucena, M Isabel | |
| dc.contributor.author | Andrade, Raul J | |
| dc.contributor.author | Wadelius, Mia | |
| dc.contributor.author | Hallberg, Pär | |
| dc.contributor.author | Stephens, Camilla | |
| dc.contributor.author | Bjornsson, Einar S | |
| dc.contributor.author | Friedmann, Peter | |
| dc.contributor.author | Kainu, Kati | |
| dc.contributor.author | Laitinen, Tarja | |
| dc.contributor.author | Marson, Anthony | |
| dc.contributor.author | Molokhia, Mariam | |
| dc.contributor.author | Phillips, Elizabeth | |
| dc.contributor.author | Pichler, Werner | |
| dc.contributor.author | Romano, Antonino | |
| dc.contributor.author | Shear, Neil | |
| dc.contributor.author | Sills, Graeme | |
| dc.contributor.author | Tanno, Luciana K | |
| dc.contributor.author | Swale, Ashley | |
| dc.contributor.author | Floratos, Aris | |
| dc.contributor.author | Shen, Yufeng | |
| dc.contributor.author | Nelson, Matthew R | |
| dc.contributor.author | Watkins, Paul B | |
| dc.contributor.author | Daly, Mark J | |
| dc.contributor.author | Morris, Andrew P | |
| dc.contributor.author | Alfirevic, Ana | |
| dc.contributor.author | Pirmohamed, Munir | |
| dc.date.accessioned | 2024-02-10T20:01:51Z | |
| dc.date.available | 2024-02-10T20:01:51Z | |
| dc.date.issued | 2019-07-03 | |
| dc.description.abstract | Carbamazepine (CBZ) causes life-threating T-cell-mediated hypersensitivity reactions, including serious cutaneous adverse reactions (SCARs) and drug-induced liver injury (CBZ-DILI). In order to evaluate shared or phenotype-specific genetic predisposing factors for CBZ hypersensitivity reactions, we performed a meta-analysis of two genomewide association studies (GWAS) on a total of 43 well-phenotyped Northern and Southern European CBZ-SCAR cases and 10,701 population controls and a GWAS on 12 CBZ-DILI cases and 8,438 ethnically matched population controls. HLA-A*31:01 was identified as the strongest genetic predisposing factor for both CBZ-SCAR (odds ratio (OR) = 8.0; 95% CI 4.10-15.80; P = 1.2 × 10-9 ) and CBZ-DILI (OR = 7.3; 95% CI 2.47-23.67; P = 0.0004) in European populations. The association with HLA-A*31:01 in patients with SCAR was mainly driven by hypersensitivity syndrome (OR = 12.9; P = 2.1 × 10-9 ) rather than by Stevens-Johnson syndrome/toxic epidermal necrolysis cases, which showed an association with HLA-B*57:01. We also identified a novel risk locus mapping to ALK only for CBZ-SCAR cases, which needs replication in additional cohorts and functional evaluation. | |
| dc.format.number | 5 | es_ES |
| dc.format.page | 1028-1036 | es_ES |
| dc.format.volume | 106 | es_ES |
| dc.identifier.doi | 10.1002/cpt.1493 | |
| dc.identifier.e-issn | 1532-6535 | es_ES |
| dc.identifier.journal | Clinical pharmacology and therapeutics | es_ES |
| dc.identifier.other | http://hdl.handle.net/10668/13926 | |
| dc.identifier.pubmedID | 31066027 | es_ES |
| dc.identifier.uri | http://hdl.handle.net/20.500.12105/17887 | |
| dc.language.iso | eng | |
| dc.rights.accessRights | open access | es_ES |
| dc.rights.license | Attribution 4.0 International | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
| dc.subject.mesh | Adult | |
| dc.subject.mesh | Anaplastic Lymphoma Kinase | |
| dc.subject.mesh | Carbamazepine | |
| dc.title | Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. | |
| dc.type | research article | |
| dc.type.hasVersion | VoR | |
| dspace.entity.type | Publication |


